JP2023528341A5 - - Google Patents
Info
- Publication number
- JP2023528341A5 JP2023528341A5 JP2022572558A JP2022572558A JP2023528341A5 JP 2023528341 A5 JP2023528341 A5 JP 2023528341A5 JP 2022572558 A JP2022572558 A JP 2022572558A JP 2022572558 A JP2022572558 A JP 2022572558A JP 2023528341 A5 JP2023528341 A5 JP 2023528341A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- product according
- administered
- fusion polypeptide
- domain variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063033074P | 2020-06-01 | 2020-06-01 | |
| US63/033,074 | 2020-06-01 | ||
| US202063106285P | 2020-10-27 | 2020-10-27 | |
| US63/106,285 | 2020-10-27 | ||
| US202063109083P | 2020-11-03 | 2020-11-03 | |
| US63/109,083 | 2020-11-03 | ||
| US202063114959P | 2020-11-17 | 2020-11-17 | |
| US63/114,959 | 2020-11-17 | ||
| US202163145925P | 2021-02-04 | 2021-02-04 | |
| US63/145,925 | 2021-02-04 | ||
| PCT/US2021/034967 WO2021247430A1 (en) | 2020-06-01 | 2021-05-28 | Combination therapies comprising a hypomethylation agent for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023528341A JP2023528341A (ja) | 2023-07-04 |
| JP2023528341A5 true JP2023528341A5 (enExample) | 2024-06-04 |
Family
ID=76808133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022572558A Pending JP2023528341A (ja) | 2020-06-01 | 2021-05-28 | 低メチル化剤を含むがんを治療するための併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12343377B2 (enExample) |
| EP (1) | EP4157315A1 (enExample) |
| JP (1) | JP2023528341A (enExample) |
| KR (1) | KR20230018475A (enExample) |
| CN (1) | CN115666620A (enExample) |
| AU (1) | AU2021283083A1 (enExample) |
| CA (1) | CA3178157A1 (enExample) |
| IL (1) | IL298644A (enExample) |
| MX (1) | MX2022014784A (enExample) |
| WO (1) | WO2021247430A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106146670B (zh) * | 2015-04-24 | 2019-01-15 | 宜明昂科生物医药技术（上海）有限公司 | 一种新的重组双功能融合蛋白及其制备和应用 |
| AU2016304794B2 (en) | 2015-08-07 | 2021-07-15 | ALX Oncology Inc. | Constructs having a SIRP-alpha domain or variant thereof |
| CN114126648A (zh) * | 2019-05-31 | 2022-03-01 | Alx肿瘤生物技术公司 | 用SIRPα Fc融合体组合免疫检查点抑制剂治疗癌症的方法 |
| CN121243368A (zh) | 2019-11-27 | 2026-01-02 | Alx肿瘤生物技术公司 | 用于治疗癌症的组合疗法 |
| KR20230018475A (ko) | 2020-06-01 | 2023-02-07 | 알렉소 온콜로지 인크. | 암 치료용 저메틸화제를 포함하는 병용 요법 |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2816647T3 (es) | 2012-01-17 | 2021-04-05 | Univ Leland Stanford Junior | Reactivos SIRP-alfa de alta afinidad |
| PL3575326T3 (pl) | 2012-12-17 | 2022-07-11 | Pf Argentum Ip Holdings Llc | Leczenie komórek chorobowych cd47+ z użyciem fuzji sirp alfa-fc |
| WO2016023040A1 (en) | 2014-08-08 | 2016-02-11 | Alexo Therapeutics International | Sirp-alpha variant constructs and uses thereof |
| EP3012271A1 (en) | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| CN106146670B (zh) | 2015-04-24 | 2019-01-15 | 宜明昂科生物医药技术（上海）有限公司 | 一种新的重组双功能融合蛋白及其制备和应用 |
| CN114425077A (zh) | 2015-05-18 | 2022-05-03 | 起源生物医药公司 | Sirp多肽组合物和使用方法 |
| AU2016304794B2 (en) | 2015-08-07 | 2021-07-15 | ALX Oncology Inc. | Constructs having a SIRP-alpha domain or variant thereof |
| WO2017068164A1 (en) | 2015-10-21 | 2017-04-27 | Ose Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
| BR112018070823A2 (pt) | 2016-04-14 | 2019-02-05 | Ose Immunotherapeutics | anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno, composição farmacêutica, produto de combinação, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, polipeptídeo, métodos para fabricar um anticorpo, in vitro ou ex vivo para determinar células positivas para sirpa, de diagnóstico e para prever a resposta de um sujeito, e, uso de um anticorpo anti-sirpa ou um fragmento de ligação a antígeno do mesmo ou um mimético de ligação a anticorpo e in vitro ou ex vivo de pelo menos um anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno. |
| AU2017250029C1 (en) | 2016-04-15 | 2022-03-24 | Pfizer Inc. | Macrophage stimulation in CD47 blockade therapy |
| CN109862910A (zh) | 2016-08-03 | 2019-06-07 | 小利兰·斯坦福大学托管委员会 | 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效 |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| CA3042583A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| CA3042581A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
| AU2017371070B2 (en) | 2016-12-09 | 2025-01-02 | Alector Llc | Anti-SIRP-alpha antibodies and methods of use thereof |
| JP7179743B2 (ja) | 2017-02-17 | 2022-11-29 | オーエスイー・イミュノセラピューティクス | 抗ＳＩＲＰｇ抗体の新規の使用 |
| CN110958888A (zh) | 2017-03-28 | 2020-04-03 | 延龄草治疗公司 | Cd47阻断疗法 |
| KR102702926B1 (ko) | 2017-04-13 | 2024-09-06 | 사이로파 비.브이. | 항-sirp 알파 항체 |
| CN118271443A (zh) | 2017-05-16 | 2024-07-02 | 拜奥迪斯私人有限公司 | 抗SIRPα抗体 |
| BR112020001653A2 (pt) | 2017-07-26 | 2020-07-21 | Forty Seven, Inc. | anticorpos anti-sirp-alfa e métodos relacionados |
| US20210347848A1 (en) * | 2018-08-31 | 2021-11-11 | ALX Oncology Inc. | Decoy polypeptides |
| CN114126648A (zh) | 2019-05-31 | 2022-03-01 | Alx肿瘤生物技术公司 | 用SIRPα Fc融合体组合免疫检查点抑制剂治疗癌症的方法 |
| US20200400662A1 (en) | 2019-06-07 | 2020-12-24 | ALX Oncology Inc. | Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays |
| ES2973832T3 (es) | 2019-10-18 | 2024-06-24 | Forty Seven Inc | Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda |
| CN121243368A (zh) | 2019-11-27 | 2026-01-02 | Alx肿瘤生物技术公司 | 用于治疗癌症的组合疗法 |
| KR20230018475A (ko) | 2020-06-01 | 2023-02-07 | 알렉소 온콜로지 인크. | 암 치료용 저메틸화제를 포함하는 병용 요법 |
| WO2022010806A1 (en) | 2020-07-06 | 2022-01-13 | ALX Oncology Inc. | Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays |
| US20220196651A1 (en) | 2020-12-06 | 2022-06-23 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
-
2021
- 2021-05-28 KR KR1020227046227A patent/KR20230018475A/ko not_active Withdrawn
- 2021-05-28 IL IL298644A patent/IL298644A/en unknown
- 2021-05-28 WO PCT/US2021/034967 patent/WO2021247430A1/en not_active Ceased
- 2021-05-28 US US17/334,151 patent/US12343377B2/en active Active
- 2021-05-28 JP JP2022572558A patent/JP2023528341A/ja active Pending
- 2021-05-28 MX MX2022014784A patent/MX2022014784A/es unknown
- 2021-05-28 EP EP21739202.6A patent/EP4157315A1/en active Pending
- 2021-05-28 CA CA3178157A patent/CA3178157A1/en active Pending
- 2021-05-28 CN CN202180039242.XA patent/CN115666620A/zh active Pending
- 2021-05-28 AU AU2021283083A patent/AU2021283083A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023528341A5 (enExample) | ||
| US12377144B2 (en) | Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen | |
| JP2023503943A5 (enExample) | ||
| JP2019530434A5 (enExample) | ||
| JP7729778B2 (ja) | Ｆｍｓ様チロシンキナーゼ３（ｆｌｔ３）に対するキメラタンパク質およびキメラタンパク質複合体 | |
| US20230416402A1 (en) | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16, and her2 | |
| AU702250B2 (en) | Methods and compositions for the specific coagulation of vasculature | |
| CN101868478B (zh) | 巨噬细胞刺激蛋白质受体(ron)的抑制及其治疗方法 | |
| JP2002514405A5 (enExample) | ||
| US20240076355A1 (en) | Interferon Prodrugs and Methods of Making and Using the Same | |
| JP2020509027A5 (enExample) | ||
| JP2007500236A5 (enExample) | ||
| CA3173919A1 (en) | Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer | |
| TW201023855A (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan | |
| IL292780A (en) | A new 4-1bbl trimer containing antigen-binding molecules | |
| JP2024520902A5 (enExample) | ||
| JP2024509018A5 (enExample) | ||
| JP2019524713A5 (enExample) | ||
| TW202330040A (zh) | 抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| JP2022513421A5 (enExample) | ||
| JP2025523369A5 (enExample) | ||
| TW201801746A (zh) | Cd33抗體藥物結合物與化學治療劑之組合 | |
| CN111936170A (zh) | 降低抗cd30抗体药物缀合物疗法的副作用的方法 | |
| US20220185857A1 (en) | Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteins | |
| CN112996540B (zh) | 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途 |